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Abstract
Aims. Common mental disorders are highly prevalent among Syrian refugees. Problem
Management Plus (PM+) is a brief, transdiagnostic, non-specialist helper delivered, psycho-
logical intervention targeting psychological distress. This single-blind pilot randomised con-
trolled trial (RCT) on PM+ delivered by peer-refugees examined trial procedures in
advance of a definitive RCT, evaluated PM+ ’s acceptability and feasibility, and investigated
its likely effectiveness and cost-effectiveness among Syrian refugees in the Netherlands.
Methods. Adult Syrian refugees (N = 60) with elevated psychological distress (Kessler
Psychological Distress Scale (K10) score >15) and reduced pychosocial functioning (WHO
Disability Assessment Schedule 2.0 (WHODAS) score >16) were randomised into PM+ in
addition to care as usual (CAU) (PM+/CAU; n = 30) or CAU alone (n = 30). Primary out-
comes were symptoms of depression and anxiety (Hopkins Symptom Checklist; HSCL-25)
at 3-month follow-up. Secondary outcomes were pychosocial functioning (WHO Disability
Assessment Schedule; WHODAS 2.0), symptoms of posttraumatic stress disorder (PTSD)
(PTSD Checklist for DSM 5; PCL-5) and self-identified problems (Psychological Outcomes
Profiles; PSYCHLOPS). Changes in service utilisation and time out of employment and/or
adult education were estimated (adapted version of the Client Service Receipt Inventory;
CSRI). Semi-structured interviews on the implementation of PM+ were conducted with
stakeholders (i.e. six PM+ participants, five non-specialist helpers and five key informants).
Results. Recruitment, randomization and blinding procedures were successful. PM+ was
generally perceived positively by stakeholders, especially regarding the intervention strategies,
accommodation of the intervention and the helpers. Two serious adverse events not attributable
to the trial were reported. At 3-month follow-up, the HSCL-25 total score was significantly lower
for the PM+/CAU group (n = 30) than CAU group (n = 30) ( p = 0.004; d = 0.58). Significant dif-
ferences in favour of PM+/CAU were also found for WHODAS psychosocial functioning ( p =
0.009, d = 0.73), PCL-5 symptoms of PTSD ( p = 0.006, d = 0.66) and PSYCHLOPS self-identified
problems ( p = 0.005, d = 0.81). There were no significant differences in mean health service costs
( p = 0.191) and themean costs of lost productive time ( p = 0.141). This suggests PM+may poten-
tially be cost-effectivewith an incremental cost from a health system perspective of €5047 (95%CI
€0–€19 773) per additional recovery achieved.
Conclusions. Trial procedures and PM+ delivered by non-specialist peer-refugee helpers
seemed acceptable, feasible and safe. Analyses indicate that PM+ may be effective in improv-
ing mental health outcomes and psychosocial functioning, and potentially cost-effective.
These results support the development of a definitive RCT with a larger sample of refugees
and a longer follow-up period.
Introduction
Recent years have witnessed a dramatic increase in the number of asylum seekers and refugees
worldwide, largely accounted for by refugees fleeing from the war in Syria to its neighbouring
countries and Europe (UNHCR, 2018). Common mental disorders are prevalent in refugees,
with estimated prevalence rates of 30.8% for depression and 30.6% for posttraumatic stress
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disorder (PTSD) (Steel et al., 2009). Recent studies among Syrian
refugees specifically also report elevated levels of distress
(Tinghög et al., 2017; Poole et al., 2018).
Refugees are individuals who are ‘unable or unwilling to return
to their country of origin owing to a well-founded fear of being per-
secuted’ (UN General Assembly, 1951). The steep increase in refu-
gees carries significant public health implications (Priebe et al.,
2016). Since the outbreak of the Syrian war, there has been an
increase in studies evaluating mental health and psychosocial sup-
port programmes for Syrian refugees in Europe (e.g. Lehnung et al.,
2017) and the Middle East (e.g. Weinstein et al., 2016).
Meta-analytic evidence supports cognitive behavioural therapy
(CBT) and narrative exposure therapy to treat PTSD in refugees
(Nosè et al., 2017; Turrini et al., 2017). Although high-income
countries such as the Netherlands have specialised mental health
staff and programmes available for refugees, the treatment gap is
large. Studies among refugees/migrants found that a large propor-
tion did not receive adequate mental health care (Lamkaddem
et al., 2014; Priebe et al., 2016). Access to specialist mental health
care is hampered by various barriers such as long waitlists, commu-
nication difficulties and stigma (Satinsky et al., 2019).
To overcome barriers to mental health care for communities
affected by adversity, the World Health Organization (WHO)
developed Problem Management Plus (PM+). PM+ is a brief,
transdiagnostic psychological intervention targeting symptoms
of depression, anxiety and distress, and is based on CBT and
problem-solving therapy strategies (Dawson et al., 2015). The
intervention comprises five face-to-face sessions with a non-
specialist helper (Dawson et al., 2015). Randomised controlled
trials (RCTs) on individual PM+ in violence-affected communi-
ties in Pakistan and Kenya showed that participants who received
individual PM+ had fewer symptoms of depression, anxiety and
PTSD, higher levels of functioning and fewer self-identified pro-
blems (Rahman et al., 2016; Bryant et al., 2017). Another RCT
on group PM+ in distressed females in the Swat area in
Pakistan showed similar results (Rahman et al., 2019).
In this study, we conducted a pilot RCT to (1) test trial procedures
in advance of the definitive RCT; (2) evaluate acceptability and feasi-
bility; and (3) gain a preliminary understanding about the likely
effectiveness and cost-effectiveness of PM+ among Syrian refugees
with elevated levels of psychological distress in the Netherlands.
Methods
Setting
The study was carried out by the Vrije Universiteit Amsterdam
(VU) in collaboration with Stichting Nieuw Thuis Rotterdam
(SNTR), a non-governmental organization (NGO) providing
support with integration, including housing, Dutch language
courses and guidance to work to approximately 200 Syrian refu-
gee families with resident status in Rotterdam. The trial was
approved by the Research Ethics Review Committee at VU
Medical Center, the Netherlands (Protocol ID: NL61361.029.17,
7 September 2017) and prospectively registered online (https://
www.trialregister.nl/trial/6665).
Study design and participants
A single-blind pilot RCT using mixed-methods was conducted
from April 2018 to May 2019. The study is part of the larger
EU H2020-funded STRENGTHS project, which aims to scale-up
brief, psychological interventions among Syrian refugees in
Europe and the Middle East (Sijbrandij et al., 2017).
CONSORT and CHEERS reporting checklists (Husereau et al.,
2013; Eldridge et al., 2016) are appended (Checklist A1 and A2).
Adult Arabic-speaking Syrian refugees (18 years or above) were
recruited during language classes and individual home visits by
SNTR staff. Inclusion criteria were elevated levels of psychological
distress as indicated by a score >15 on the Kessler Psychological
Distress Scale (K10) (Kessler et al., 2002) and impaired daily func-
tioning, indicated by a score >16 on the WHO Disability
Assessment Schedule 2.0 (WHODAS 2.0; Ustun et al., 2010).
Exclusion criteria were acute medical conditions, imminent suicide
risk (assessed with the PM+ manual suicidal thoughts interview)
(WHO, 2016), expressed acute needs or protection risks, indica-
tions of severe mental disorders (e.g. psychotic disorders) or cogni-
tive impairment (e.g. severe intellectual disability; assessed by the
PM+ manual observation checklist) (WHO, 2016).
Procedures
Oral and written informed consent (IC) was obtained from all
participants before screening. Included participants completed
baseline assessment questionnaires and were randomised into
PM+/care as usual (CAU) or CAU alone by an independent
researcher not involved in the study. CAU comprises all other
mental health services available to Syrian refugees in the
Netherlands (e.g. community services and non-directive counsel-
ling by local NGOs, or referral to specialised PTSD treatment
such as narrative exposure therapy). Randomization with block
size 6 was performed using software on a 1:1 basis. Participants
were phoned on group allocation by an Arabic-speaking team
member not involved in assessments. Participants randomised
to PM+/CAU were directly contacted by their helper to plan
the first session within 1 week after baseline assessment.
Post- and 3-month follow-up assessments were scheduled 1
week after the 5th PM+ session (or 6 weeks after baseline) and 3
months after the 5th PM+ session. Assessments were carried out
by two Arabic-speaking assessors who received a 3-day training
on questionnaire administration, general interview techniques,
common mental disorders, psychological first aid and ethical
research conduct. Assessors were blinded to condition and indi-
cated after each post- and follow-up assessment whether group
allocation was disclosed to them (i.e. yes PM+/CAU; yes CAU; no).
Problem Management Plus (PM+)
The PM+ intervention has five 90 min sessions, delivered weekly.
Four components are introduced by the helper, including a slow
breathing exercise, problem-solving strategy, behavioural activa-
tion through re-engaging with pleasant and task-oriented activ-
ities, and accessing social support. A detailed description of
PM+ is available (Dawson et al., 2015). The PM+ manual was
translated/culturally adapted for use among Syrian refugees
through qualitative study (cf. Applied Mental Health Research
Group, 2013) and by using a framework for the cultural adapta-
tion of psychological interventions (Bernal and Sáez-Santiago,
2006; see de Graaff et al., 2020).
The intervention was delivered by eight Arabic-speaking Syrian
non-specialist helpers already working as ‘connectors’ at SNTR.
They received 8 days of training followed by weekly face-to-face
group supervision by PM+ trainers/supervisors throughout the
trial. Training involved education about common mental disorders,
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basic counselling skills, delivery of intervention strategies and self-
care (WHO, 2016). Supervision included discussion of individual
cases and difficulties experienced by helpers, practice of skills
and self-care (WHO, 2016). Helpers had at least high school edu-
cation, a background in social work, teaching or another related
field, and sufficient Dutch or English speaking ability. Trainers/
supervisors were mental health care professionals who underwent
5-day training covering elements of the training of helpers, as
well as training and supervision skills (cf. Rahman et al., 2016).
A 25% random sample of the audio recordings was independ-
ently coded by two research assistants for adequate delivery of
PM+ treatment elements (yes/no) through a checklist addressing
requisite PM+ components per session (see appendedChecklist A3).
Primary outcome measure
Symptoms of anxiety and depression. The 25-item Hopkins
Symptom Checklist (HSCL-25) (Arabic version) (Derogatis
et al., 1974; Selmo et al., 2016) was used to measure symptoms
of anxiety (10 items) and depression (15 items). Item mean scores
(range 1–4) were analysed.
Secondary outcome measures
Functional impairment. The WHODAS 2.0 is a well-accepted,
validated 12-item instrument to assess health and disability
(Ustun et al., 2010). Items are rated on a 1–5 scale (range 12–60).
Posttraumatic stress symptoms. The Arabic version of the
20-item PTSD Checklist for DSM-5 (PCL-5) (Blevins et al.,
2015; Ibrahim et al., 2018) assesses PTSD symptoms on a 0–4
scale (range 0–80).
Self-identified problems. The Psychological Outcomes Profiles
(PSYCHLOPS) (Ashworth et al., 2004) questionnaire is a patient-
generated indicator of change after therapy. It covers
self-identified problems and function (both free-text fields), and
wellbeing scored on a 0–5 scale (range 0–20).
Client Service Receipt Inventory (CSRI). The CSRI (Beecham
and Knapp, 1992) was modified for use in Syrian refugees in
the Netherlands to self-report health service utilization, receipt
of informal family care and participation in employment/
education or other productive use of time over 3 months.
Other measures
Trauma exposure. Life-time traumatic experiences were mea-
sured through a 27-item checklist (Schick et al., 2016) adapted
for this project. Items were scored 1 (yes) or 0 (no), total range
0–27.
Post-migration stressors. The Post-Migration Living Difficulties
checklist (Arabic version) (Silove et al., 1997; Schick et al.,
2016) assesses 17 post-migration challenges scored on a 0–4
scale. Items with at least a score of 2 (moderately serious problem)
were considered positive responses and summed for analysis
(range 0–17).
These measures were used for descriptive analyses.
Quantitative and qualitative analyses
To compare reductions in primary/secondary outcomes between
groups across three time points in the intention-to-treat sample
(N = 60), we used linear mixed models in RStudio version 3.6.1
(R Core Team, 2018). This method allows the number of
observations to vary between participants and handles missing out-
come data. The mixed model uses a longitudinal data structure that
includes both fixed and random effects. Time (categorical), group
(PM+/CAU v. CAU) and interactions between group and time
were included as fixed effects in mixed models together with a ran-
dom intercept and random time effect. Differences in least-squares
means (intervention effects) at each time point with 95% confi-
dence intervals were derived. Cohen’s d for the effect of the inter-
vention was estimated by calculating the difference between
estimated means (corrected for baseline) divided by raw pooled
standard deviation. A two-sided p < 0.05 indicated statistical signifi-
cance. As this study’s primary intention was to test feasibility and
acceptability, it was not powered to detect significant differences.
The reliable change index was used to evaluate whether parti-
cipants have reliable and clinically significant change scores from
baseline to post- and follow-up (Jacobson and Truax, 1991).
The economic analysis was performed from both a healthcare
system and a broader perspective, including productivity impacts
on participants and their families. Health service utilization and
productivity losses were estimated across all time points. PM+
training, supervision resource and delivery costs were obtained
from project records. Unit costs were attached to health service
utilization using published tariffs used in the Netherlands
(Hakkaart-van Roijen et al., 2015). Medication reimbursement
rates were obtained from the Netherlands National Health Care
Institute (Zorginstituut Nederland, 2020). See Appendix
Table A1 for unit costs used. All patient and family productivity
losses were valued using age-specific 2018 minimum wage rates
(Government of the Netherlands, 2020). All costs are 2018
euros and discounting was not applied given the short study dur-
ation. Given the skewed distribution of costs, differences in mean
costs were compared between the two groups using bias-corrected
and accelerated (BCa) bootstrapping 1000 times. Incremental
cost-effectiveness ratios (ICERs) per additional recovery and
improvement without recovery at 3-month follow-up were calcu-
lated. Statistical uncertainty was explored through bootstrapping
1000 randomly resampled pairs of costs and outcomes.
Cost-effectiveness acceptability curves (CEACs) were generated
to show the likelihood PM+ is cost-effective at different willing-
ness to pay levels.
Semi-structured interviews were audio recorded and tran-
scribed verbatim in interview language (Arabic, Dutch or
English). Arabic transcripts were translated into English by
bi-lingual research assistants. Deidentified transcripts were
analysed thematically and independently by two researchers
(AdG and AW) in NVivo (QSR International Pty Ltd, 2015).
Inductive analysis was used to categorise data and elicit themes.
Findings were discussed by these researchers and a final coding
framework agreed and then applied to all transcripts.
Results
Objective 1: testing trial procedures
Recruitment and consent rates
Recruitment occurred from April to November 2018. In total, 205
individuals gave permission to SNTR staff to be contacted by the
VU research team. Of these, 110 declined, ten were unreachable
and five did not attend screening. Eighty-one participants gave
IC and were screened for eligibility to participate. Of these, 60 par-
ticipants were included and randomised into PM+/CAU (n = 30)
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or CAU alone groups (n = 30). Figure 1 presents the CONSORT
flow diagram.
Group allocation and blinding
An SNTR team-leader matched PM+ participants to helpers.
During the trial, we decided to ask all participants at the screening
interview whether they preferred matching with a male or female
helper to facilitate the matching procedures; however, female
helpers preferred not to be matched to male participants.
Blinding was successful in 47% of outcome assessments.
Attendance and follow-up assessments
Assessments occurred between May 2018 and March 2019.
Twenty-eight (93.3%) of the 30 participants allocated to PM+/
CAU completed all five sessions. Two stopped after sessions 1
and 2 because the spouse did not allow participation and due
to lack of time. Three months post-intervention, data were
obtained from 54 participants, with 86.7% completing all assess-
ments. Reported reasons for non-attendance across assessments
were ‘prefers to withdraw’ (n = 3), ‘lack of time’ (n = 3), ‘abroad/
unavailable’ (n = 1) and ‘no approval from spouse’ (n = 1). In
23% of outcome assessments, assessors assisted participants by
reading questionnaires aloud.
PM+ protocol fidelity assessment
Fifty per cent (n = 15) of PM+/CAU participants agreed to have
their sessions audiorecorded. Two research assistants scored
25% (n = 18 tapes) of 72 available audiorecorded sessions after
five practice tapes scored by both research assistants (Cohen’s
κ = .80). Fidelity checks indicated helpers adhered to 76.6% of
the PM+ protocol. Helpers completed 27 checklists, reporting
93.7% completion of the PM+ protocol.
Objective 2: experiences with PM+ and barriers to treatment
Semi-structured interviews with six PM+ participants, five helpers
and five key informants explored experiences with PM+, accept-
ability and feasibility in addition to barriers and facilitators of
Fig. 1. CONSORT flow-diagram.
4 A. M. de Graaff et al.
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PM+ implementation. Quotes (Q) are depicted in Appendix
Table A2.
Experiences with the PM+ intervention
Interviewees spoke generally positively about the PM+ interven-
tion (Q1.1) and strategies (Q1.2–3). Its therapeutic effect on
participant mental health (Q1.5–6), as well as that of helpers
(Q1.7), was the dominant reason for holding a positive view.
Helpers stressed breaking homework into small feasible steps
would improve adherence (Q1.8). According to helpers, partici-
pants generally became more motivated and confident about
the intervention after their first positive experience in applying
a learned strategy. Some participants said they started to forget
about strategies after completing PM+ (Q1.9), and several partici-
pants and helpers thought PM+ might be too brief (Q1.10–12).
Perceived facilitators of PM+ adherence were related to the
accommodation of the programme for participants (e.g. travel
expense coverage, flexibility scheduling sessions) and helpers
(e.g. time reserved to conduct PM+ sessions and supervision
during working hours, ability to decrease caseload) (Q1.13–15).
Overall, participants did not disclose their participation in
PM+ for fear of gossip and ridicule (Q1.16). However, a few
said they shared their PM+ experiences with family members
and practised strategies with them. A challenge to intervention
adherence was the ‘busy lives’ (H1) of some participants.
Views on the helper
Participants and helpers mentioned they quickly established
rapport and trust and felt comfortable sharing their stories and
problems (Q2.1). Two participants even called their helper a
‘friend’ (Q2.2).
All interviewees spoke about the importance of PM+ being in
Arabic, as it facilitated communication and self-expression (Q2.3–
4). Having a similar background was generally found supportive
for building rapport, although it was mentioned that it could
cause distrust. For example, one participant was initially appre-
hensive because the helper was Syrian but later found their shared
experiences beneficial (Q2.5). Participants appreciated similarities
with their helper, but also that the helper was otherwise a stranger
(Q2.6–8), creating a confidential and safe environment (Q2.9).
Generally, participants perceived their helper as competent
(Q2.10–11). One participant commented that if the helper was
a professional, he may have benefitted more (Q2.12).
Information on experiences in training and supervision of
helpers is provided in Appendix Table A2.
Objective 3: estimating likely effectiveness and
cost-effectiveness
Treatment effect
Two serious adverse events related to domestic violence were
reported to the Research Ethics Review Committee. Table 1
shows demographic characteristics, traumatic events and post-
migration stressors. Table 2 presents findings on primary out-
comes of anxiety and depression (HSCL-25), and secondary out-
comes of functional impairment (WHODAS 2.0), symptoms of
PTSD (PCL-5) and self-identified problems (PSYCHLOPS) in
PM+/CAU and CAU groups at all time points. There were no sig-
nificant group differences between participants who were lost to
Table 1. Demographic characteristics
Total sample (N = 60) PM + /CAU (n = 30) CAU (n = 30)
Age, M (S.D.) 38.1 (12.2) 37.6 (11.8) 38.6 (12.7)
Sex, male n (%) 24 (40.0) 12 (40.0) 12 (40.0)
Marital status n (%),a Never married 6 (10.2) 3 (10.3) 3 (10.0)
Currently married 42 (71.2) 20 (69.0) 22 (73.3)
Separated 4 (6.8) 2 (6.7) 2 (6.7)
Divorced 6 (10.2) 3 (10.0) 3 (10.0)
Widowed 1 (1.7) 1 (3.3) 0 (0.0)
Cohabiting 0 (0.0) 0 (0.0) 0 (0.0)
Education (highest started), n (%)a
No or basic education 30 (50.8) 15 (51.7) 15 (50.0)
Secondary education 20 (33.9) 7 (24.1) 13 (43.4)
Higher education (at least Bachelor) 9 (15.3) 7 (24.1) 2 (6.7)
Post-migration stressors, M (S.D.) 7.0 (3.3) 7.3 (3.6) 6.6 (3.0)
Total number of life-time traumatic events, M (S.D.) 10.2 (6.2) 9.0 (5.7) 11.5 (6.5)
Most reported traumatic event types, n (%), Civilian in war zone 46 (76.7) 23 (76.7) 23 (76.7)
In danger during the flight 40 (66.7) 21 (70.0) 19 (63.3)
Forced separation from family member 37 (61.7) 17 (56.7) 20 (66.7)
Unnatural death of family member or friend 37 (61.7) 18 (60.0) 19 (63.3)
Lack of shelter 35 (58.3) 17 (56.7) 18 (60.0)
aData not obtained for one PM+/CAU participant, valid per cent reported.
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follow-up v. those retained. The pattern of missing data is
presented in Appendix Table A3.
Primary outcomes
Linear mixed models in the intention-to-treat sample for the
HSCL-25 total score showed a significant effect of time, moder-
ated by condition (χ2(2) = 10.41; p = 0.005). In the PM+/CAU
group, overall HSCL-25 scores decreased relative to the CAU
group (see Fig. 2). Post-hoc tests showed PM+/CAU relative to
the CAU had lower scores 1 week (mean [standard deviation]
1.86 [0.58] v. 2.38 [0.65]; adjusted mean difference (AMD),
0.45; 95% CI 0.29–0.61, p = 0.005) and 3 months after the inter-
vention (1.92 [0.62] v. 2.42 [0.59]; AMD 0.48; 95% CI 0.32–
0.65, p = 0.004). Effects sizes were moderate to large (d = 0.54
and d = 0.58, respectively) (Table 2).
For HSCL-25 anxiety, the effect of time was significant, and
this was moderated by condition (χ2(2) = 7.58; p = 0.022). In the
PM+/CAU group, anxiety decreased relative to the CAU group.
Post-hoc contrasts showed a medium effect post-assessment
(1.76 [0.62] v. 2.22 [0.71]; AMD 0.41; 95% CI 0.24–0.57, p =
0.017, d = 0.48), and at 3-month follow-up (1.94 [0.68] v. 2.38
[0.64]; AMD 0.43; 95% CI 0.25–0.60, p = 0.016, d = 0.48).
We also found a significant effect of time for HSCL-25 depres-
sion, moderated by condition (χ2(2) = 8.58; p = 0.013). In the
PM+/CAU group, depression decreased relative to the CAU
group. Post-hoc contrasts showed a medium effect post-assessment
(1.93 [0.66] v. 2.48 [0.68]; AMD 0.49; 95% CI 0.32–0.66, p = 0.005,
d = 0.50) and at 3-month follow-up (1.91 [0.63] v. 2.45 [0.63];
AMD 0.52; 95% CI 0.35–0.70, p = 0.003, d = 0.52).
Secondary outcomes
Linear mixed models furthermore showed a significant inter-
action effect in favour of PM+/CAU between time and condition
for psychosocial functioning (WHODAS 2.0; χ2(2) = 12.99; p =
0.001), symptoms of PTSD (PCL-5; χ2(2) = 9.07; p = 0.010) and
self-identified problems (PSYCHLOPS; χ2(2) = 10.51; p = 0.005).
Post-hoc contrasts at 3-month follow-up showed the PM+/CAU
group relative to the CAU group had higher levels of psychosocial
functioning (23.65 [6.40] v. 30.15 [10.05]; AMD 6.42; 95% CI
4.01–8.83, p = 0.009), and decreased scores for PTSD symptoms
(20.21 [17.51] v. 34.12 [17.14]; AMD 13.35; 95% CI 8.67–18.03,
p = 0.006) and self-identified problems (9.71 [5.71] v. 15.12
[7.40]; AMD 5.25; 95% CI 3.45–7.05, p = 0.005). Moderate to
large effects were found (d = 0.73, d = 0.66, d = 0.81, respectively).
Analyses with PM+ completers only (n = 28) v. CAU (n = 30)
indicated similar results (Appendix Table A4).
Reliable change index for symptoms of anxiety and depression
At 3-month follow-up, 14 PM+/CAU participants had a reliable
change on HSCL-25 total score, of which three were clinically sig-
nificant (i.e. recovered). In the CAU group, six participants had a
reliable decrease in HSCL-25 scores, while two had a reliable
increase in scores (i.e. deteriorated) (Appendix Table A5).
Table 2. Summary statistics and results from mixed-model analysis of primary and secondary outcomes
Descriptive statistics, M (S.D.) Mixed-model analysisa
Outcomes Time point PM+/CAU (n = 30) CAU (n = 30) Difference in LS mean (95% CI) p-value Effect sizea
HSCL-25 total Baseline 2.42 (0.54) 2.55 (0.65)
Post-assessment 1.86 (0.58) 2.38 (0.65) 0.45 (0.29–0.61) 0.005 0.54
Follow-up 1.92 (0.62) 2.42 (0.59) 0.48 (0.32–0.65) 0.004 0.58
HSCL anxiety Baseline 2.32 (0.63) 2.41 (0.63)
Post-assessment 1.76 (0.62) 2.22 (0.71) 0.41 (0.24–0.57) 0.017 0.48
Follow-up 1.94 (0.68) 2.38 (0.64) 0.43 (0.25–0.60) 0.016 0.48
HSCL depression Baseline 2.48 (0.55) 2.64 (0.72)
Post-assessment 1.93 (0.66) 2.48 (0.68) 0.49 (0.32–0.66) 0.005 0.50
Follow-up 1.91 (0.63) 2.45 (0.63) 0.52 (0.35–0.70) 0.003 0.52
WHODAS 2.0 Baseline 32.13 (7.57) 30.52 (7.51)
Post-assessment 24.19 (9.16) 27.77 (9.37) 3.32 (1.15–5.49) 0.130 0.53
Follow-up 23.65 (6.40) 30.15 (10.05) 6.42 (4.01–8.83) 0.009 0.73
PCL-5 Baseline 35.46 (18.04) 37.25 (17.11)
Post-assessment 21.41 (16.06) 34.50 (15.47) 11.13 (6.73–15.53) 0.013 0.59
Follow-up 20.21 (17.51) 34.12 (17.14) 13.35 (8.67–18.03) 0.006 0.66
PSYCHLOPS Baseline 15.54 (2.56) 15.47 (3.95)
Post-assessment 9.81 (5.92) 13.52 (4.89) 3.23 (1.83–4.63) 0.022 0.62
Follow-up 9.71 (5.71) 15.12 (7.40) 5.25 (3.45–7.05) 0.005 0.81
M, mean; S.D., standard deviation; LS mean, least-squares mean.
HSCL-25 = 25-item Hopkins Symptoms Checklist (range item-mean = 1–4, higher scores indicate elevated anxiety or depression); WHODAS 2.0 = WHO Disability Assessment Schedule 2.0
(range 12–60, higher scores indicate worse functional impairment); PCL-5 = PTSD Checklist for DSM-5 (range 0–80, higher scores indicate greater severity); PSYCHLOPS = Psychological
Outcomes Profiles (range 0–20, higher scores indicate poorer outcome).
aEffect sizes are determined by calculating the difference between the estimated means (corrected for baseline) divided by the raw pooled standard deviation.
6 A. M. de Graaff et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S2045796020000724
Downloaded from https://www.cambridge.org/core. IP address: 82.36.73.222, on 18 Aug 2020 at 09:34:42, subject to the Cambridge Core terms of use, available at
Economic analysis
At 3-month follow-up, mean costs per PM+/CAU participant were
significantly higher than in CAU participants from a health service
perspective (€888.75 [S.D. €432.24] v. €347.97 [326.93]; MD €540.78;
95% CI €336.17–€755.78, p = 0.001) (Table 3). Excluding PM+
training, supervision and delivery, costs remained non-significantly
higher for PM+/CAU (€485.65 [€432.24] v. €347.97 [326.93]; MD
€137.67; 95% CI €–67.71 to €355.53, p = 0.195).
Fig. 2. HSCL-25 total score across time points.
Table 3. Mean health and productivity costs (2018 euros) per participant at 3-month follow-up
Type of cost PM+/CAU (n = 28) CAU (n = 26) Mean difference (BCa 95% CI) p
PM+ intervention costs
PM+ intervention, M (S.D.) 403.10 (0) 0 (0) 403.10 (403.10–403.10) 0.000
Health service utilisation, M (S.D.)
Community health worker 5.14 (12.83) 2.08 (5.86) 3.07 (−1.64 to 8.63) 0.260
Community-based doctor 61.93 (79.63) 51.00 (90.85) 10.93 (−38.36 to 56.03) 0.641
Psychiatrist 45.50 (129.25) 18.85 (55.57) 26.65 (−15.59 to 86.93) 0.325
Psychologist 35.89 (155.25) 10.31 (41.05) 25.59 (−16.75 to 91.12) 0.407
Psychiatric nurse 0.00 (0.00) 3.46 (12.49) −3.46 (−9.00 to 1.24) 0.135
Social worker 99.57 (192.76) 94.15 (150.31) 5.42 (−83.66 to 96.26) 0.908
Physiotherapist 78.93 (205.27) 40.54 (125.76) 38.39 (−44.74 to 138.50) 0.408
Other health professionals 90.64 (58.27) 96.23 (58.92) −5.59 (−36.95 to 27.78) 0.728
Hospital inpatient stays – general health 35.36 (187.09) 0.00 (0.00) 35.36 (−29.12 to 134.97) 0.139
Hospital outpatient services – general health 30.54 (58.12) 25.58 (78.60) 4.96 (−36.28 to 41.64) 0.795
Medications 2.15 (8.33) 5.78 (15.81) −3.63 (−11.29 to 3.23) 0.303
Total health service utilisation costs 485.65 (432.24) 347.97 (326.93) 137.67 (−67.71 to 355.53) 0.195
Total health system costs, M (S.D.) 888.75 (432.24) 347.97 (326.93) 540.78 (336.17–755.78) 0.001
Productivity losses, M (S.D.) 28.91 (102.78) 297.15 (894.29) −268.24 (−719.91 to 6.76) 0.325
Total health and productivity costs, M (S.D.) 917.65 (453.28) 645.12 (1149.46) 272.53 (−338.81 to 711.02) 0.368
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Productivity costs were non-significantly lower for PM+/CAU
participants (€28.91 [102.78] v. €297.15 [894.29]; MD €268.24;
95% CI €–719.91 to €6.76, p = 0.325). Overall costs between
PM+/CAU and CAU did not differ significantly (€917.65
[€453.28] v. €645.12 [1149.46]; MD €272.53; 95% CI €–338.81
to €711.02, p = 0.368).
Table 4 summarises results of the exploratory cost-effectiveness
analysis. From a health system perspective, PM+/CAU had an
ICER of €5047 (95% CI €0–€19 773) per additional recovery
achieved. This was €2266 (95% CI €–1070 to €15 930) when prod-
uctivity losses averted were included. Cost-effectiveness planes in
Figs A1-A2 (Appendix) indicate when productivity losses are con-
sidered PM+/CAU may even have both better outcomes and lower
costs than CAU. The ICER per additional improvement on the
HSCL-25 without recovery was €2009 (95% CI €0–€2406). Figs
A3–A6 (Appendix) show cost-effectiveness planes and CEACs
per additional improvement without recovery.
While no accepted cost-effectiveness threshold for recovery
from depression and anxiety exists, CEAC indicate at least an
85% chance that PM+/CAU is cost-effective if funders are willing
to pay €10 000 per recovery (Figs A7-A8 in Appendix). (In the
Netherlands, €20 000 per additional year lived in full quality
health is usually considered cost-effective; Brouwer et al. (2019).)
Discussion
This pilot RCT aimed to test trial procedures, treatment facilita-
tors and barriers, and likely effectiveness and cost-effectiveness
of PM+ among Syrian refugees in the Netherlands. Our findings
suggest that the adapted PM+ protocol is acceptable for use
among Syrian refugees. Participants, helpers and key informants
were generally positive about the intervention, including the
PM+ strategies, accommodation (e.g. reimbursement of travel
expenses) and delivery by Syrian helpers. Training and structural
supervision of peer-refugees was perceived feasible and accept-
able. These findings are further supported by helpers’ adherence
to the protocol and low participant drop-out from the interven-
tion. Two adverse events unlikely attributable to the trial or inter-
vention were reported by participants, suggesting that PM+ is a
safe intervention. However, some participants may have experi-
enced shame from trial participation.
Although the study was not powered to detect significant dif-
ferences, depression and anxiety symptoms improved in the PM+/
CAU group relative to the CAU group, with moderate effect sizes.
The study also indicated moderate to large improvements in over-
all psychosocial functioning, PTSD symptoms and self-identified
problems. No significant difference in health service utilisation or
costs was observed between groups, but overall costs were signifi-
cantly higher in PM+/CAU due to PM+ implementation costs.
Mean intervention costs ultimately are likely to be lower if trainers
and helpers can be retained and continue to deliver PM+ to more
refugees over a longer time period. Nonetheless, our exploratory
economic analysis suggests PM+ has the potential to be cost-
effective from a health system perspective.
The moderate improvements across a broad range of symp-
toms are in line with previous PM+ trials (Rahman et al., 2016;
Bryant et al., 2017), and support the intervention’s transdiagnostic
feature (Dawson et al., 2015). One key finding is that, although
PM+ is not a trauma-focused intervention, it improved PTSD
symptomatology in this war-affected sample. This adds to existing
literature indicating PTSD symptoms can be successfully treated
with brief, non-trauma-focused interventions (Nidich et al.,
2018; Turrini et al., 2019).
This is the first study exploring how PM+ can be delivered by
peer-refugees in a high-income country. Although refugees are
typically exposed to ongoing post-migration stressors, our study
showed that effects were retained up to 3 months. A key strength
in this study is the mixed-methods design that enabled us to
examine both quantitative outcomes in a rigorous RCT, as well
as perceptions of various stakeholders about the acceptability
and feasibility of PM+. Another strength is the use of the second-
ary outcome measure PSYCHLOPS, which examines participant-
generated problems, instead of ‘Western’ mental health con-
structs. Furthermore, we added the WHODAS measure of overall
psychosocial functioning to look beyond mental health and psy-
chosocial problems, something often not included in the evalu-
ation of psychosocial interventions for refugees (Turrini et al.,
2019).
Our study also has a number of limitations. First, we failed to
interview study drop-outs in our qualitative evaluation, limiting
our insights on barriers to trial participation. Second, although
treatment effects and cost-effectiveness results are promising,
they should be interpreted with caution as no power calculations
were carried out. Furthermore, participants were recruited from a
foundation established for Syrian families with resident status liv-
ing in an urban area, and results might be different for those still
awaiting completion of their asylum procedure.
A major practical implication of the present pilot RCT is that
the study and PM+ procedures can be successfully carried out
among Syrian refugees. The observed low drop-out is promising
for a definite RCT. Use of Audio-Computer-Assisted
Self-Interview software (e.g. Morina et al., 2017) that does not
require administration by an assessor may improve blinding.
Longer term follow-up is needed to better assess whether there
is an impact on health service utilization and social functioning
outcomes such as participation in work and study. With a larger
sample size, it will also be possible to estimate changes in quality
of life outcomes, using a generic outcome measure such as the
Quality Adjusted Life Year (QALY), a metric that has resonance
with policy makers. Replication in a fully-powered RCT is needed
Table 4. Exploratory cost-effectiveness analyses (2018 euros)
Health system
perspective
Likelihood
cost-effective
Health system and
productivity loss perspective
Likelihood
cost-effective
Incremental cost per recovery achieved at
3-month follow-up (95% CI)a
€5047 (€0–€19 773) 85% €2266 (€–1070 to €15 930) 93%
Incremental cost per improvement achieved
at 3-month follow-up (95% CI)b
€2009 (€0–€2406) 93% €902 (€–276 to €1813) 98%
aAssumes a willingness to pay of €10 000 per recovery on the HSCL-25 achieved.
bAssumes a willingness to pay of €2000 per significant improvement on the HSCL-25 achieved.
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(see De Graaff et al., 2020). Other trials on PM+ with different
modes of delivery (e.g. group) will be conducted in the larger
STRENGTHS project (Sijbrandij et al., 2017). This will strengthen
the external validity of trial findings and provide a potential
model for scaling up in more and less well-resourced contexts.
Conclusion
This study indicates that the trial procedures and PM+ delivered
by peer-refugee, non-specialist helpers are acceptable, feasible and
safe. PM+ is likely effective in improving mental health outcomes
and psychosocial functioning in Syrian refugees, and potentially
cost-effective. A fully-powered, definitve RCT with longer
follow-up is needed.
Data. The Vrije Universiteit Amsterdam (VU) will keep a central data reposi-
tory of all data collected in the STRENGTHS project. The data will be available
upon reasonable request to the STRENGTHS consortium. Data access might
not be granted to third parties when this would interfere with relevant data
protection and legislation in the countries participating in this project and
any applicable EU legislation regarding data protection. Interested researchers
can contact Dr Marit Sijbrandij at e.m.sijbrandij@vu.nl to initiate the process.
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Appendices
Appendix 1: Checklists
Checklist A1. CONSORT 2010 Checklist of information to include when reporting a pilot or feasibility trial
Section/topic
Item
No Checklist item
Reported on
page No
Title and abstract
1a Identification as a pilot or feasibility randomised trial in the title 1
1b Structured summary of pilot trial design, methods, results, and conclusions (for
specific guidance see CONSORT abstract extension for pilot trials)
1
Introduction
Background and objectives 2a Scientific background and explanation of rationale for future definitive trial, and
reasons for randomised pilot trial
1–2
2b Specific objectives or research questions for pilot trial 2
Methods
Trial design 3a Description of pilot trial design (such as parallel, factorial) including allocation ratio 2
3b Important changes to methods after pilot trial commencement (such as eligibility
criteria), with reasons
N/A
Participants 4a Eligibility criteria for participants 2
4b Settings and locations where the data were collected 2
4c How participants were identified and consented 2
Interventions 5 The interventions for each group with sufficient details to allow replication,
including how and when they were actually administered
2–3
Outcomes 6a Completely defined prespecified assessments or measurements to address each
pilot trial objective specified in 2b, including how and when they were assessed
3
6b Any changes to pilot trial assessments or measurements after the pilot trial
commenced, with reasons
4
6c If applicable, prespecified criteria used to judge whether, or how, to proceed with
future definitive trial
N/A
Sample size 7a Rationale for numbers in the pilot trial 2
7b When applicable, explanation of any interim analyses and stopping guidelines N/A
Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence 2
8b Type of randomisation(s); details of any restriction (such as blocking and block size) 2
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation sequence (such as
sequentially numbered containers), describing any steps taken to conceal the
sequence until interventions were assigned
2
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and
who assigned participants to interventions
2
Blinding 11a If done, who was blinded after assignment to interventions (for example,
participants, care providers, those assessing outcomes) and how
2
11b If relevant, description of the similarity of interventions N/A
Statistical methods 12 Methods used to address each pilot trial objective whether qualitative or
quantitative
3
Results
Participant flow (a diagram is
strongly recommended)
13a For each group, the numbers of participants who were approached and/or assessed
for eligibility, randomly assigned, received intended treatment, and were assessed
for each objective
3–4 + Fig. 1
13b For each group, losses and exclusions after randomisation, together with reasons 3–4 + Fig. 1
Recruitment 14a Dates defining the periods of recruitment and follow-up 3–4
14b Why the pilot trial ended or was stopped 4
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 5(Table 1)
(Continued )
Epidemiology and Psychiatric Sciences 11
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S2045796020000724
Downloaded from https://www.cambridge.org/core. IP address: 82.36.73.222, on 18 Aug 2020 at 09:34:42, subject to the Cambridge Core terms of use, available at
Checklist A1. (Continued.)
Section/topic Item
No
Checklist item Reported on
page No
Numbers analysed 16 For each objective, number of participants (denominator) included in each analysis.
If relevant, these numbers should be by randomised group
3–8 + Fig. 1
Outcomes and estimation 17 For each objective, results including expressions of uncertainty (such as 95%
confidence interval) for any estimates. If relevant, these results should be by
randomised group
5–8
Ancillary analyses 18 Results of any other analyses performed that could be used to inform the future
definitive trial
5–8
Harms 19 All important harms or unintended effects in each group (for specific guidance see
CONSORT for harms)
5
19a If relevant, other important unintended consequences N/A
Discussion
Limitations 20 Pilot trial limitations, addressing sources of potential bias and remaining
uncertainty about feasibility
8
Generalisability 21 Generalisability (applicability) of pilot trial methods and findings to future definitive
trial and other studies
8–9
Interpretation 22 Interpretation consistent with pilot trial objectives and findings, balancing potential
benefits and harms, and considering other relevant evidence
8–9
22a Implications for progression from pilot to future definitive trial, including any
proposed amendments
8–9
Other information
Registration 23 Registration number for pilot trial and name of trial registry 9
Protocol 24 Where the pilot trial protocol can be accessed, if available N/A
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 9
26 Ethical approval or approval by research review committee, confirmed with
reference number
2
Checklist A2. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Checklist
Section/topic # Recommendation
Reported on
page #/line #
TITLE AND ABSTRACT
Title 1 Identify the study as an economic evaluation or use more specific terms such as
‘cost-effectiveness analysis’, and describe the interventions compared
1
Abstract 2 Provide a structured summary of objectives, perspective, setting, methods
(including study design and inputs), results (including base case and uncertainty
analyses), and conclusions
1
INTRODUCTION
Background and objectives 3 Provide an explicit statement of the broader context for the study
Present the study question and its relevance for health policy or practice
decisions
1–2
METHODS
Target population and subgroups 4 Describe characteristics of the base case population and subgroups analysed,
including why they were chosen
2
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be
made
2
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated 3
Comparators 7 Describe the interventions or strategies being compared and state why they were
chosen
2–3
(Continued )
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Checklist A2. (Continued.)
Section/topic # Recommendation Reported on
page #/line #
Time horizon 8 State the time horizon(s) over which costs and consequences are being
evaluated and say why appropriate
3
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why
appropriate
3
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in the
evaluation and their relevance for the type of analysis performed
3
Measurement of effectiveness 11a Single study-based estimates: Describe fully the design features of the single
effectiveness study and why the single study was a sufficient source of clinical
effectiveness data
2–3
11b Synthesis-based estimates: Describe fully the methods used for identification of
included studies and synthesis of clinical effectiveness data
N/A
Measurement and valuation of
preference based outcomes
12 If applicable, describe the population and methods used to elicit preferences for
outcomes
N/A
Estimating resources and costs 13a Single study-based economic evaluation: Describe approaches used to estimate
resource use associated with the alternative interventions. Describe primary or
secondary research methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to opportunity costs
2–4
13b Model-based economic evaluation: Describe approaches and data sources used
to estimate resource use associated with model health states. Describe primary
or secondary research methods for valuing each resource item in terms of its
unit cost. Describe any adjustments made to approximate to opportunity costs
N/A
Currency, price date, and conversion 14 Report the dates of the estimated resource quantities and unit costs. Describe
methods for adjusting estimated unit costs to the year of reported costs if
necessary. Describe methods for converting costs into a common currency base
and the exchange rate
3
Choice of model 15 Describe and give reasons for the specific type of decision-analytical model
used. Providing a figure to show model structure is strongly recommended
N/A
Assumptions 16 Describe all structural or other assumptions underpinning the
decision-analytical model
N/A
Analytical models 17 Describe all analytical methods supporting the evaluation. This could include
methods for dealing with skewed, missing, or censored data; extrapolation
methods; methods for pooling data; approaches to validate or make
adjustments (such as half cycle corrections) to a model; and methods for
handling population heterogeneity and uncertainty
N/A
RESULTS
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for
all parameters/Report reasons or sources for distributions used to represent
uncertainty where appropriate. Providing a table to show the input values is
strongly recommended
Appendix
Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated
costs and outcomes of interest, as well as mean differences between the
comparator groups. If applicable, report incremental cost-effectiveness ratios
Table 3 and 4
Characterising uncertainty 20a Single study-based economic evaluation: Describe the effects of sampling
uncertainty for the estimated incremental cost and incremental effectiveness
parameters, together with the impact of methodological assumptions (such as
discount rate, study perspective)
8+ Appendix
20b Model-based economic evaluation: Describe the effects on the results of
uncertainty for all input parameters, and uncertainty related to the structure of
the model and assumptions
N/A
Characterising heterogeneity 21 If applicable, report differences in costs, outcomes, or cost-effectiveness that can
be explained by variations between subgroups of patients with different baseline
characteristics or other observed variability in effects that are not reducible by
more information
N/A
DISCUSSION
Study findings, limitations,
generalisability, and current
knowledge
22 Summarise key study findings and describe how they support the conclusions
reached. Discuss limitations and the generalisability of the findings and how the
findings fit with current knowledge
8–9
(Continued )
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Checklist A2. (Continued.)
Section/topic # Recommendation Reported on
page #/line #
Other
Source of funding 23 Describe how the study was funded and the role of the funder in the
identification, design, conduct and reporting of the analysis. Describe other
non-monetary sources of support
9
Conflicts of interest 24 Describe any potential for conflict of interest of study contributors in accordance
with journal policy. In the absence of a journal policy, we recommend authors
comply with International Committee of Medical Journal Editors
recommendations
9
Checklist A3. Individual PM+ helper’s component checklist
SESSION 1
No. Item Components Checklist COMPLETED? NOTES
YES NO
1.1 Conduct
Introductions and explain
Confidentiality
1.1a – Introduce yourself
1.1b – Explain concept of confidentiality, including information about when
confidentiality can be broken
1.1c – Answer participant questions about PM+ intervention and sessions if
needed
1.1d – Ask permission for making audio recordings of the sessions (sign IC form)
1.2 Introduce What is PM+? 1.2a – Explain PM+ intervention to the participant
1.2b – Discuss participant’s reasons for and challenges to attending PM+ sessions
1.2c – Support participant to manage any obstacles to attending sessions
1.3 Conduct What is Adversity? 1.3a – Define adversity using participant’s examples
1.3b – Discuss and normalize common reactions to adversity
1.3c – Discuss how PM+ aims to help participants manage their problems
1.4 Teach and practice Managing
Stress Exercise
1.4a – Provide information on how stress affects the body
1.4b – Relate the information to participant’s physical/tension problems
1.4c – Teach and practice breathing from the diaphragm/stomach (show balloon)
1.4d – Practice slow breathing together
1.4e – Discuss challenges and difficulties
1.5 Use appropriate psychosocial
communication skills
1.5a – Appropriate eye contact, facial expression, and body
1.5b – Demonstrate a non-judgmental attitude
1.5c – Appropriate use of non-verbal communication
1.5d – Communicate concern and validate participant
1.6 Incorporate safety management
skills
1.6a – Review for suicidality if necessary
1.6b – Identify potentials risks of harm to self or others
1.6c – Use techniques for acute management of risk and provide referral
1.7 Closing Procedures 1.7a – Review session and schedule home practice
1.7b – Information of next session (remind date, time, place and strategy)
SESSION 2
No. Item Components Checklist COMPLETED? NOTES
YES NO
2.1 Incorporate safety management
skills
2.1a – Review for suicidality if necessary
2.1b – Identify potentials risks of harm to self or others
2.1c – Use techniques for acute management of risk and provide referral
(Continued)
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2.2 Welcome and review Managing
Stress
2.2a – Welcome the participant back
2.2b – Discuss questions participant has about Session 1
2.2c – Review participant’s Managing stress home practice
2.2d – Help managing any difficulties with home practice
2.3 Introduce Managing Problems 2.3a – Introduce strategy Managing problems for practical problems
2.3b – Explain each of the 7 steps
2.3c – Help the participant to apply the strategy to a chosen problem
2.3d – Help the participant develop and action plan
2.3e – Give participant Managing Problems handout
2.4 Practice Managing Stress 2.4a – Practice slow breathing together
2.4b – Discuss challenges and difficulties
2.5 Uses appropriate psychosocial
communication skills
2.5a – Appropriate eye contact, facial expression, and body
2.5b – Demonstrate a non-judgmental attitude
2.5c – Appropriate use of non-verbal communication
2.5d – Communicate concern and validate participant
2.6 Incorporate safety management
skills
2.6a – Review for suicidality if necessary
2.6b – Identify potentials risks of harm to self or others
2.6c – Use techniques for acute management of risk and provide referral
2.7 Closing Procedures 1.7a – Review session and schedule home practice
1.7b – Information of next session (remind date, time, place and strategy)
SESSION 3
No. Item Components Checklist COMPLETED? NOTES
YES NO
3.1 Incorporate safety management
skills
3.1a – Review for suicidality if necessary
3.1b – Identify potentials risks of harm to self or others
3.1c – Use techniques for acute management of risk and provide referral
3.2 Welcome and review Managing
Stress
3.2a – Welcome the participant back
3.2b – Discuss questions participant has about previous sessions
3.2c – Review participant’s Managing stress home practice
3.2d – Help manage any difficulties with home practice
3.3 Review Managing Problems 3.3a – Discuss participant’s experiences of completing their Action Plan for
Managing Problems
3.3b – Respond to and manage any difficulties (e.g. unable to complete,
encountered problems when completing)
3.3c – Help participant apply strategy to continue managing the same problem or
a new problem
3.4 Introduce Get Going and Keep
Doing and the Inactivity cycle
3.4a – Introduce Get Going and Keep Doing strategy
3.4b – Show the Inactivity Cycle and explain
3.4c – Discuss how inactivity cycle can be broken
3.4d – Give participant Get Going and Keep Doing handout
3.5 Apply Get Going Keep Doing with
an enjoyable activity
3.5a – Help participant to select an enjoyable activity
3.5b – Help participant break down their activity into small steps
3.5c – Help participant develop their action plans
3.6 Practice Managing Stress 3.6a – Practice slow breathing together
3.6b – Discuss challenges and difficulties
3.7 Use appropriate psychosocial
communication skills
3.7a – Appropriate eye contact, facial expression, and body
3.7b – Demonstrate a non-judgmental attitude
(Continued)
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3.7c – Appropriate use of non-verbal communication
3.7d – Communicate concern and validate participant
3.8 Incorporate safety management
skills
3.8a – Review for suicidality if necessary
3.8b – Identify potentials risks of harm to self or others
3.8c – Use techniques for acute management of risk and provide referral
3.9 Closing Procedures 3.9a – Review session and schedule home practice
3.9b – Information of next session (remind date, time, place and strategy)
SESSION 4
No. Item Components Checklist COMPLETED? NOTES
YES NO
4.1 Incorporate safety management
skills
4.1a – Review for suicidality if necessary
4.1b – Identify potentials risks of harm to self or others
4.1c – Use techniques for acute management of risk and provide referral
4.2 Welcome and review Managing
Stress
4.2a – Welcome the participant back
4.2b – Discuss questions participant has about previous sessions
4.2c – Review participant’s Managing stress home practice
4.2d – Help manage any difficulties with home practice
4.3 Review Managing Problems 4.3a – Discuss participant’s experiences of completing their Action Plan for
Managing Problems
4.3b – Respond to and manage any difficulties (e.g. unable to complete,
encountered problems when completing)
4.3c – Help participant apply strategy to continue managing the same problem or
a new problem
4.4 Review Get Going Keep Doing 4.4a – Discuss participant’s experiences of completing their Action Plan for Get
Going Keep Doing
4.3b – Respond to and manage any difficulties (e.g. unable to complete,
encountered problems when completing)
4.3c – Help participant apply strategy to continue with the same activity or start a
new activity (task-oriented activity)
4.5 Introduce Strengthening Social
Support
4.5a – Define Strengthening Social Support
4.5b – Discuss different social supports and how they can be helpful
4.5c – Give participant Strengthening Social Supports handout
4.6 Apply Strengthening Social
Support
4.6a – Help participant identify how they can strengthen their social support
4.6b – Help participants develop an action plan
4.6c – Rehearse with participants what they will do/say in their action plan if
applicable
4.7 Practice Managing Stress 4.7a – Practice slow breathing together
4.7b – Discuss challenges and difficulties
4.8 Use appropriate psychosocial
communication skills
4.8a – Appropriate eye contact, facial expression, and body
4.8b – Demonstrate a non-judgmental attitude
4.8c – Appropriate use of non-verbal communication
4.8d – Communicate concern and validate participant
4.9 Incorporate safety management
skills
4.9a – Review for suicidality if necessary
4.9b – Identify potentials risks of harm to self or others
4.9c – Use techniques for acute management of risk and provide referral
4.10 Closing Procedures 3.10a – Review session and schedule home practice
3.10b – Information of next session (remind date, time, place and strategy)
(Continued)
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SESSION 5
No. Item Components Checklist COMPLETED? NOTES
YES NO
5.1 Incorporate safety management
skills
5.1a – Review for suicidality if necessary
5.1b – Identify potentials risks of harm to self or others
5.1c – Use techniques for acute management of risk and provide referral
5.2 Welcome and review all PM+ home
practice
5.2a – Welcome the participant back
5.2b – Discuss questions participant has about previous sessions
5.2c – Review Managing Stress home practice
5.2d – Review Managing Problems home practice
5.2e – Review Get Going Keep Doing home practice
5.2f – Review Strengthening Social Support home practice
5.2g – Manage any difficulties participants had with any of their home practice
5.3 Complete Staying Well 5.3a – Congratulate the participant on finishing PM+
5.3b – Discuss participant improvements and areas for continued work
5.3c – Emphasize importance of continuing to practice PM+ strategies, using
learning a new language example
5.3d – Discuss potential future problems and how participant can respond
5.4 Complete How to help others 5.4a – Use the case examples to discuss how the participant could help others
experiencing problems
5.4b – Discuss their responses and correct any misunderstandings
5.5 Complete Looking Forward 5.5a – Review goals that were not achieved
5.5b – Discuss how the participant can work towards these goals
5.5c – Help participants to identify new goals
5.6 Use appropriate psychosocial
communication skills
5.6a – Appropriate eye contact, facial expression, and body
5.6b – Demonstrate a non-judgmental attitude
5.6c – Appropriate use of non-verbal communication
5.6d – Communicate concern and validate participant
5.7 Incorporate safety management
skills
5.7a – Review for suicidality if necessary
5.7b – Identify potentials risks of harm to self or others
5.7c – Use techniques for acute management of risk and provide referral
5.8 Closing Procedures 5.8a – Review session and schedule home practice
5.8b – Information of next session (remind date, time, place and strategy)
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Appendix 2: Tables
Table A1. Unit cost (2018 euros)
Type of cost
Unit
cost Unit Source
Community health worker (assumed to be equivalent to nurse practitioner) €18 Per consultation Hakkaart-van Roijen et al. (2015)
Community-based doctor €34 Per consultation Hakkaart-van Roijen et al. (2015)
Psychiatrist €98 Per consultation Hakkaart-van Roijen et al. (2015)
Psychologist €67 Per consultation Hakkaart-van Roijen et al. (2015)
Psychiatric nurse €18 Per consultation Hakkaart-van Roijen et al. (2015)
Social worker (maatschappelijk werk) €68 Per consultation Hakkaart-van Roijen et al. (2015)
Physiotherapist €34 Per session Hakkaart-van Roijen et al. (2015)
Other health professionals (assumed same as community health worker) €18 Per consultation Hakkaart-van Roijen et al. (2015)
Hospital inpatient stays – general health (weighted average for general and
university hospitals)
€495 Per day Hakkaart-van Roijen et al. (2015)
Hospital outpatient services – general health (weighted average for general
and university hospitals)
€95 Per visit Hakkaart-van Roijen et al. (2015)
Hospital A&E €269 Per visit Hakkaart-van Roijen et al. (2015)
Medications (Tramadol) €0.11 Per 50 mg
capsule
Zorginstituut Nederland (2020)
Medications (Duloxetine) €0.06 Per 30 mg
capsule
Zorginstituut Nederland (2020)
Minimum wage rate aged 20 (July 2018) €51.51 Per day Government of the Netherlands (2020)
Minimum wage rate aged 21 (July 2018) €63.39 Per day Government of the Netherlands (2020)
Minimum wage rate aged 22+ (July 2018) €74.58 Per day Government of the Netherlands (2020)
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Table A2. Qualitative analysis themes and related quotes
Themes Interviewee # Selected quotes
Theme 1
Experiences with the PM+ intervention
- Positive effects P1 Q1.1 The positive point is that they [helpers] can understand the problem. And they can find solutions. They can think in a different way. A way
different from ours, different from the routine way of thinking. They provide relaxation.
P3 Q1.2 First thing is the breathing, because as I get angry, this breathing technique is very useful.
P6 Q1.3 Like language, I can attend free courses or [visit] the neighbour’s house. (…) It was one of the [practical] problems I can solve. But the
problem that they may remove me back to Syria, no one can predict what would happen after a year and half. So it does not have a solution.
P3 Q1.4 In the past my husband was telling me ‘let’s go somewhere’ and I was saying ‘no I don’t feel like.’ So I am breaking this routine and maybe I
am resting and maybe enjoying or maybe the opposite but the positives are more than the negatives.
P4 Q1.5 From the inside I felt better.
KI3 Q1.6 They [PM+ participants] gave examples like; that they used the daily [PM+] strategies and that they carried out the breathing exercises on a
daily basis. And they also mentioned examples of how they benefitted from it. That was a good check for me; what has it [PM+] brought?
KI4 Q1.7 And they [helpers] kept repeating that it [PM+] was really useful for themselves. When they started doing the [PM+] training. For example,
understanding their own fears and experiences but also in their own families.
- Adherence to strategies H2 Q1.8 With some [participants] it [PM+ strategies] went smooth, with others you had to repeat it and practice it again and make it smaller, make it
softer, so that they would at some point taste and feel the experience.
P1 Q1.9 I almost continued for one month after the end of the [intervention]. I kept using the same style. But after, I didn’t continue. I forgot about it
to be honest. But sometimes I think about it. When I have problems (…) Then, I remember the breathing technique.
- Duration of PM + P4 Q1.10 Yes, I wanted us to be in contact and he keeps asking me about my problems and follows me up.
H5 Q1.11 For one participant who does not have much stress it is doable, but for the other, it might be too brief.
H3 Q1.12 And I think that some people need nothing more than the intervention itself to continue with the strategies, but maybe for others it would
be good to match them to something that will help them and reminds them of [PM+]. I don’t know how, maybe via trainings or a YouTube
channel or a website or something, yes.
- Barriers/facilitators
- Time/emotional burden
- Accommodation
- Stigma
KI1 Q1.13 We [SNTR] tried to take away all the logistical barriers [to participate in PM+] like covering their transport to the location and making it like a
free programme.
H1 Q1.14 But what’s good is that we always heard that if it is too much you can tell this and you don’t have to take any new participants for a while or
you can say that you can only have one participant per week.
P1 Q1.15 The appointment [of PM+ sessions] was exact and everything was perfect.
P6 Q1.16 I told two people [about my participation in the project] I felt that they started laughing (…) I felt that they are making fun of it. So, I didn’t
tell anyone after.
Theme 2
Views on the helper
- Rapport and trust P3 Q2.1 In Syria, people with mental problems are called crazy. The [helper] isn’t a psychiatrist but someone you speak to about your problems and
maybe she can help you finding a solution. This is how I liked the program and liked participating.
P2 Q2.2 I considered her a friend. Not a durable friendship but friendship in the session’s time. I was feeling comfortable talking to her.
- Similar culture/experiences/
language
P1 Q2.3 Because he [helper] is from the same country I was able to communicate with him easily. And speak my native language Arabic without any
language barriers.
KI3 Q2.4
(Continued )
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Table A2. (Continued.)
Themes Interviewee # Selected quotes
And especially the group of people that is not familiar in talking about their mental health, I think it will be so hard for them to find the right
words to express themselves in their second language.
P6 Q2.5 When I talk about anything, he [helper] could directly understand why I am talking like this. Maybe he went through same conditions like
me.
- Helper is ‘neutral’ H5 Q2.6 In PM+ they will be with Syrian people, from their own culture, from their own language, but not people that they know, not family or so, so
they will talk.
KI5 Q2.7 And some [participants] don’t tell their families [about PM+]. They come here in secret; they don’t want anyone to know.
KI2 Q2.8 We have two teams [at SNTR]: a South team and a North team. Some [PM+] helpers were working in the South team and others in the
North. And if it was possible, I would exchange them; if a participant was from team South, I would try to find a helper from the North.
P3 Q2.9 I felt good with her [helper] and safe…because maybe I can’t share these things that are inside me with someone that I know.
- Competence P2 Q2.10 Her [helper] answers were convincing. You feel that she is a competent helper.
P1 Q2.11 Even if he is not professional, he was well trained.
P5 Q2.12 But as I told you, I couldn’t take him [helper] as seriously as I would with a professor, as it is coming from a person not specialized and
hasn’t studied at the university.
Theme 3
Experiences of training and supervision
- Experiences of PM + training and
supervision
KI5 Q3.1 But it is, as trainer, really, yes, hard work. Because you have to learn a lot [as helper] and you notice that during supervision afterwards they
still grow. You have to repeat the basics for quite some time. Because they [PM+ helpers] might start doing other things.
H1 Q3.2 Of course the first and or second time were exciting. We often had to turn to the protocol, so to say. Up to now we do that, but I notice that
there are many things we say automatically, without asking help we do it ourselves. You can learn a lot about the PM+ strategies from
practical experience. But the first knowledge by a specialist and having enough time and enough explanation through the training was very
good.
- Supervision as:
- Further training ground
- Space to discuss cases
- Source of emotional support
H4 Q3.3 Of course, we also had weekly supervision, so we talk about it. We are very clear and open about the difficulties we face, how we can better
approach it, from how other colleagues dealt with it.
H2 Q3.4 And with the supervisor of course you can always ask about it, learn more, ask questions about how you can deal with it in another way.
H4 Q3.5 But some people maybe they need extra help, but we also indicate this if we notice this. So we talk about it with our supervisor and then we
will see what is best for our participants.
KI5 Q3.6 Yes because they [helpers] also recognize the stories [of PM+ participants]. So that was something we took into consideration. Yes. So on the
one hand it was good in terms of recognition, but on the other hand it was difficult for them [helpers].
H5 Q3.7 [The PM+ participants] sometimes come with very heavy stories and we are people, too, of course. But I always try to protect myself and find
distraction, or in supervision it is good to talk about it of course. I also talk with other colleagues, that helps me too. To express my story.
H, helper; KI, key informant; P, PM+ participant; SNTR, Stichting Nieuw Thuis Rotterdam.
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Theme 3: Experiences of training and supervision
The PM+ supervisor described the weekly supervisions as ‘hard work’
because the helpers had no background in psychology (KI5). Both supervisor
and helpers experienced that further practice of PM+ skills during supervision
increased helpers’ ability to model the strategies to participants and adhere to
the protocol (Q3.1–2). Helpers described supervision as a way ‘to learn from
each other’ (H2) and ‘improve their approach’ (H4) (Q3.3). Communication
between supervisors and helpers was in Dutch, but some of the role-play
was in Arabic (to practice how PM+ will work with participants).
Individual case monitoring was mainly used to support tailoring PM+ to
the individual (Q3.4), and to detect and potentially refer those with possibly
more severe mental health problems (e.g. substance abuse) to professional
care (Q3.5). Several KIs, however, expressed concerns about the current wait-
ing lists for such professional help.
Recognition of participants’ stories was helpful though potentially burden-
some for helpers (Q3.6). They explained that hearing about other people’s pro-
blems could be challenging, but that supervision and talking to colleagues
helped them (Q3.7). The supervisor emphasised the importance of self-care
during supervision, given the similarity of experiences (emotional burden),
and because helpers carried out the sessions alongside their regular work for
SNTR (time burden). Both helpers and the supervisor spoke about the import-
ance of knowing ‘your limits’ as helper. One helper was asked to briefly
put PM+ as extra activity in her regular work ‘on hold’ due to signs of
burn-out.
Table A3. Missing data pattern
Time point
Group Outcome measure Baseline (N = 60) Post-assessment (N = 53) 3-month follow-up (N = 54)
Whole sample HSCL-25, n of missing items (%) 6 (0.4) 7 (0.5) 2 (0.1)
WHODAS 2.0, n of missing items (%) 1 (0.1) 3 (0.5) 1 (0.2)
PCL-5, n of missing items (%) 9 (0.8) 0 (0) 0 (0)
PSYCHLOPS, n of missing items (%) 7 (2.9) 1 (0.5) 1 (0.5)
Total, n of missing items (%) 23 (0.6) 11 (0.3) 4 (0.1)
PM+/CAU HSCL-25, n of missing items (%) 4 (1.1) 4 (0.6) 1 (0.1)
WHODAS 2.0, n of missing items (%) 0 (0) 1 (0.3) 1 (0.3)
PCL-5, n of missing items (%) 7 (1.2) 0 (0) 0 (0)
PSYCHLOPS, n of missing items (%) 7 (5.8) 0 (0) 0 (0)
Total, n of missing items (%) 18 (0.9) 5 (0.3) 2 (0.1)
CAU HSCL-25, n of missing items (%) 2 (0.6) 3 (0.5) 1 (0.2)
WHODAS 2.0, n of missing items (%) 1 (0.3) 2 (0.6) 0 (0)
PCL-5, n of missing items (%) 2 (0.3) 0 (0) 0 (0)
PSYCHLOPS, n of missing items (%) 0 (0) 1 (1.0) 1 (1.0)
Total, n of missing items (%) 5 (0.3) 6 (0.4) 2 (0.1)
PM/CAU, Problem Management Plus and care as usual group; CAU, care as usual control group.
The percentage of missed assessments (unit non-response; Brick and
Kalton, 1996) in the study was 7.2%. Eighty-seven per cent (86.7%) of parti-
cipants completed all three assessments. There were more assessment skips
in the CAU group (13% at both post and 3-month follow-up) than in the
PM+/CAU group (10% at post and 6.7% at 3-month follow-up). Reported rea-
sons for non-attendance across assessments were ‘prefer to withdraw’ (n = 3),
‘lack of time’ (n = 3), ‘abroad/unavailable’ (n = 1), and ‘no approval from
spouse’ (n = 1).
The percentage of missing items (item non-response; Brick and Kalton,
1996) across the primary outcome variable HSCL-25 and secondary outcome
variables WHODAS 2.0, PCL-5 and PSYCHLOPS varied between 0.1–2.9%
(baseline), 0–0.5% (post-assessment) and 0–0.5% (3-month follow-up). We
assumed data to be missing at random (Little and Rubin, 2002). Table A3 pre-
sents missing values per outcome variable.
We used pro-rated, single imputations for outcome measures with missing
items. We did not impute unit non-response, as linear mixed-models in R
handle missing outcome data (Raudenbush, 2001).
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Table A4. Summary statistics and results from mixed-model analysis of primary and secondary outcomes without PM+ non-completers
Descriptive statistics, M (S.D.) Mixed model analysisa
Outcomes Time point PM+/CAU (n = 28) CAU (n = 30) Difference in LS mean (95% CI) p-value Effect sizea
HSCL-25 total Baseline 2.43 (0.56) 2.55 (0.65)
Post-assessment 1.86 (0.58) 2.38 (0.65) 0.45 (0.287–0.611) 0.007 0.62
Follow-up 1.92 (0.63) 2.42 (0.59) 0.48 (0.317–0.651) 0.005 0.59
HSCL anxiety Baseline 2.34 (0.64) 2.41 (0.63)
Post-assessment 1.76 (0.62) 2.22 (0.71) 0.40 (0.229–0.569) 0.021 0.49
Follow-up 1.92 (0.64) 2.38 (0.64) 0.43 (0.255–0.607) 0.017 0.56
HSCL depression Baseline 2.48 (0.57) 2.64 (0.72)
Post-assessment 1.93 (0.66) 2.48 (0.68) 0.49 (0.311–0.663) 0.006 0.49
Follow-up 1.92 (0.64) 2.45 (0.63) 0.52 (0.345–0.697) 0.004 0.57
WHODAS 2.0 Baseline 32.25 (7.83) 30.52 (7.51)
Post-assessment 24.19 (9.16) 27.77 (9.37) 3.32 (1.10–5.64) 0.141 0.54
Follow-up 23.45 (6.43) 30.15 (10.05) 6.55 (4.28–8.82) 0.004 0.97
PCL-5 Baseline 35.59 (18.14) 37.25 (17.11)
Post-assessment 21.41 (16.06) 34.50 (15.47) 11.18 (6.71–15.65) 0.014 0.59
Follow-up 20.25 (17.85) 34.12 (17.14) 13.35 (8.85–18.41) 0.006 0.75
PSYCHLOPS Baseline 15.44 (2.56) 15.47 (3.95)
Post-assessment 9.81 (5.92) 13.52 (4.89) 3.28 (1.87–4.69) 0.022 0.61
Follow-up 9.62 (5.81) 15.12 (7.40) 5.34 (3.51–7.17) 0.005 0.81
HSCL-25 = 25-item Hopkins Symptoms Checklist (range item-mean = 1–4, higher scores indicate elevated anxiety or depression); WHODAS 2.0 = WHO Disability Assessment Schedule 2.0
(range 12–60, higher scores indicate worse functional impairment); PCL-5 = PTSD Checklist for DSM-5 (range 0–80, higher scores indicate greater severity); PSYCHLOPS = Psychological
Outcomes Profiles (range 0–20, higher scores indicate poorer outcome); M = mean; S.D. = standard deviation.
aEffect sizes are determined by calculating the difference between the estimated means (corrected for baseline) divided by the raw pooled standard deviation.
Table A5. Reliable change index at post-assessment and 3-month follow-up for the HSCL-25 (completers only)
Post-assessment Follow-up
RCI PM + /CAU (n = 27) CAU (n = 26) PM + /CAU (n = 28) CAU (n = 26)
Recovered, n (%)a 2 (7.4%) 0 (0%) 3 (10.7%) 0 (0%)
Improved without recovery, n (%)b 11 (40.7%) 7 (26.9%) 11 (39.3%) 6 (23.1%)
Deteriorated, n (%)b 0 (0%) 1 (3.8%) 0 (0%) 2 (7.7%)
No change, n (%) 14 (51.9%) 18 (69.2%) 14 (50.0%) 18 (69.2%)
RCI, reliable change index.
aThe Clinical Significant Change cut-off for the HSCL-25 (total scale) was calculated by subtracting 2 S.D. of the baseline M for the full sample.
bThe RCI for the HSCL-25 (total score) was calculated using the baseline S.D. for the full sample and baseline Cronbach’s α as test-retest reliability coefficient (Jacobson and Truax, 1991).
Recovered = clinical significant reliable change; Improved without recovery = no clinical significant reliable change; Deteriorated = reliable change with worsening of symptoms; No change =
no reliable change.
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Fig. A1 Cost-effectiveness plane: PM+/CAU v. CAU per recovery achieved (health sys-
tem perspective).
Fig. A3 Cost-effectiveness plane: PM+/CAU v. CAU per improvement achieved (health
system perspective).
Fig. A4 Cost-effectiveness plane: PM+/CAU v. CAU per recovery achieved (health sys-
tem and productivity loss perspective).
Fig. A2 Cost-effectiveness plane: PM+/CAU v. CAU per recovery achieved (health sys-
tem and productivity perspective).
Appendix 3: Figures
Fig. A5 Cost-effectiveness acceptability curve: willingness to pay per improvement
achieved from PM+/CAU intervention (health system perspective).
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Fig. A7 Cost-effectiveness acceptability curve: willingness to pay per recovery
achieved from PM+/CAU intervention (health system perspective).
Fig. A6 Cost-effectiveness acceptability curve: willingness to pay per improvement
achieved from PM+/CAU intervention (health system perspective).
Fig. A8 Cost-effectiveness acceptability curve: willingness to pay per recovery
achieved from PM+/CAU intervention (health system and productivity perspective).
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